Bio-Gene Technology Ltd.
AASX:BGT0.01
AUD
0.00
(0.00%)
ISIN
AU000000BGT8
Return %
Stock
S&P 500
1Y
-48.15
14.20
3Y
-80.00
81.12
5Y
-89.63
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Tim Grogan
- Full Time Employees
- 5
- Sector
- Process industries
- Industry
- Chemicals: agricultural
- Address
- 456 Lonsdale Street Melbourne VIC Australia 3000
- IPO Date
- Nov 29, 2017
- Website
- bio-gene.com.au
- Similar Companies
- Business
- Bio-Gene Technology Limited Bio-Gene Technology Limited (ASX:BGT) is an Australian agtech development company that engages in the research, development, and commercialization of novel bio-insecticides derived from naturally occurring beta-triketone compounds to overcome global insecticide resistance challenges while minimizing impacts on human health and the environment. The company's core products include Flavocide, a synthetic beta-triketone molecule formulated as an emulsion in water (EW) for agricultural crop protection, grain storage, public health mosquito and tick control, animal health, and consumer applications; and Qcide, a natural oil insecticide extracted via steam distillation from the leaves of the rare Australian eucalypt cultivar Gympie Messmate (Eucalyptus cloeziana), containing tasmanone as the active constituent and recently approved by the Organic Materials Review Institute (OMRI) for listing as a botanical pesticide under the USDA National Organic Program. These patent-protected platforms target pests across crop protection, grain storage, public health, animal health, and consumer segments, with operations primarily in Australia and expanding internationally. Founded in 1995 and headquartered at 400 Collins Street, Level 6, Melbourne, Victoria 3000, Australia, Bio-Gene Technology Limited operates in the biotechnology and agriculture technology sectors, serving growers, grain handlers, public health authorities, and consumer markets in Australia, North America, South America, Central America, and select international regions. Recent developments include the successful completion of pilot-scale production of pre-commercial quantities of Flavocide in partnership with Rallis India Limited, enabling capacity for future commercial supply to licensees; a strategic collaboration with Clarke Mosquito Control for public health applications of Flavocide and Qcide across the Americas; a team-up with BASF and the Queensland Department of Agriculture & Fisheries to advance Flavocide for stored grain pest control in Australia; presentation of strong Flavocide efficacy data against Lyme disease-carrying ticks at the International Conference on Lyme Borreliosis by Purdue University researchers; a A$2.1 million funding placement in May 2025 to support regulatory studies for Flavocide, Qcide scale-up, product development tied to partnerships, and working capital; and key milestones in grain storage trials confirming Flavocide's compliance with industry standards against pests like the lesser grain borer.